Dapagliflozin in heart failure and type 2 diabetes: Efficacy, cardiac and renal effects, safety

Table 2 Comparison of clinical characteristics between the two groups of patients

Clinical characteristics	Control group (n = 51)	Study group (n = 51)	χ2/t	P value
Gender
Male	31	28	0.362	0.547
Female	20	23
Age (yr)	70.86 ± 3.99	71.04 ± 3.19	-0.247	0.805
Systolic blood pressure (mmHg)	127.51 ± 12.03	126.71 ± 12.41	0.332	0.74
Diastolic blood pressure (mmHg)	81.88 ± 6.98	81.47 ± 9.93	0.242	0.809
Heart rate (times/min)	80.20 ± 10.11	80.49 ± 10.76	-0.142	0.887
Fasting plasma glucose (mmol/L)	8.12 ± 0.75	8.03 ± 0.79	0.606	0.546
2 h postprandial glucose (mmol/L)	11.30 ± 0.78	11.44 ± 1.04	-0.775	0.44
Glycated hemoglobin (%)	8.53 ± 0.54	8.42 ± 0.63	0.948	0.346
BMI (kg/m2)	23.20 ± 1.34	23.08 ± 1.81	0.393	0.696
NYHA score
III	32	33	0.042	0.837
IV	19	18
History of coronary heart disease
Yes	44	46	0.378	0.539
No	7	5
History of hypertension
Yes	33	28	1.02	0.313
No	18	23
Medications for heart failure treatmen
Spironolactone	44	48	1.774	0.183
Other	7	3
Glucose-Lowering agents
Acarbose	27	25	0.157	0.692
Other	24	26

BMI: Body mass index; NYHA: New York Heart Association.